Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 17/20 | 0.75 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.68 |
| ▸ | MLKL | Q8NB16 | 2/20 | 0.68 |
| ▸ | RIPK3 | Q9Y572 | 2/20 | 0.68 |
| ▸ | AURKA | O14965 | 1/20 | 0.68 |
| ▸ | KIT | P10721 | 2/20 | 0.55 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17260948 | 0.95 | KDR (0.79) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL4811434 | 0.86 | KDR (1.00) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17979841 | 0.84 | KDR (0.70) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17979939 | 0.83 | KDR (0.79) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17261018 | 0.83 | KDR (0.79) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17979866 | 0.82 | KDR (0.78) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17260951 | 0.82 | KDR (0.77) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17979850 | 0.82 | KDR (0.69) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17980324 | 0.82 | KDR (0.67) | KDRRIPK1MLKLRIPK3AURKA | |
| SCHEMBL17261227 | 0.82 | KDR (0.67) | KDRRIPK1MLKLRIPK3AURKA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | CATALYST THERAPEUTICS PTY LTD (AU) | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114025-A1 | METHODS FOR INHIBITING NECROPTOSIS | RIPK1, RIPK3, RIPK2 | KDR 4376/4885RIPK1 1/4885MLKL 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.